Journal of Psychoactive Drugs
March 3, 2025
Wayne Kepner, Patricia Dionicio, Katie Bailey et al.
3 citations
Little is known about ecstasy/MDMA use among Asian American and Pacific Islander populations. Research is important because AAPIs face unique cultural factors that may influence use. We estimated the prevalence and correlates of lifetime ecstasy/MDMA use based on a representative sample of US AAPI adults aged ≥18 from the 2015-2020 National Survey on Drug Use and Health. An estimated 5.1% of...
Journal of Psychoactive Drugs
March 1, 2025
Alexsandra Kovacevich, Ian Dorney, Lukas Bobak et al.
1 citation
Olfactory dysfunction (OD) has become increasingly prevalent since the COVID-19 pandemic, yet effective treatments remain limited. In recent years, anecdotal reports have emerged on the potential benefits of serotonergic psychedelics (lysergic acid diethylamide [LSD], psilocybin, etc.) in improving OD. To date, only one case series in the medical literature has documented this phenomenon. This...
Journal of Psychoactive Drugs
February 20, 2025
Broc A. Pagni, Andreas Halman, Jerome Sarris et al.
7 citations
The durability of ayahuasca's effects on mental health and the influence of clinical diagnoses on therapeutic response is unclear. Adults with no prior exposure to ayahuasca (n = 66) participating in neo-shamanic ayahuasca ceremonies completed questionnaires at baseline, 7 days, and 1, 6, and 12 months. Mixed models were used to characterize temporal trajectories in mental health, alcohol and...
Journal of Psychoactive Drugs
February 13, 2025
Stanisław Adamczyk, Małgorzata Paczyńska, Anastasia Ruban et al.
2 citations
Psychedelics have the potential to induce profound alterations in cognition, emotionality, and sensory perception. The quality and intensity of these subjective effects exhibit high intra- and inter-individual variability, which can potentially be accounted for by the variability in contexts in which psychedelics are used. Therefore, the aim of the present cross-sectional study was to...
Journal of Psychoactive Drugs
February 13, 2025
Yitong Xin, Roland R. Griffiths, Alan K. Davis
1 citation
An interesting aspect of entity encounters during psychedelic experiences is their ability to transform one's religious beliefs. However, little is known about sex differences in these transformations. This study investigates sex differences in changes in religious beliefs before and after an entity encounter among ayahuasca users. Data were collected via an anonymous Internet-based survey (N =...
Journal of Psychoactive Drugs
February 7, 2025
Amy Lehrner, Heather Jackson, David S. Mathai et al.
11 citations
The classic psychedelic psilocybin has attracted special interest across clinical and non-clinical settings as a potential tool for mental health. Despite increasing attention to challenging psychedelic experiences, few studies have explored the relevance of shame-related processes with psychedelic use. This prospective, longitudinal study involved sequential, automated, web-based surveys that...
Journal of Psychoactive Drugs
February 5, 2025
Daniel J. Kruger, Jeff Albrecht, Jacob S. Aday et al.
3 citations
Psychedelic drugs are currently being explored for their therapeutic potential for a variety of health conditions. The recent increased public interest in psychedelics necessitates empirical investigation into motivations for use among users as well as how motivations may change over time. We asked a large sample of participants reporting naturalistic psychedelic use (N = 1221) about their...
Journal of Psychoactive Drugs
January 29, 2025
Jason B. Luoma, Kim Hoffman, Adrianne R Wilson-Poe et al.
3 citations
New legal frameworks for supervised psychedelic services are emerging, with Oregon and Colorado implementing programs to train and license psilocybin facilitators. This study describes Oregon's early psilocybin facilitator workforce and assesses state-approved training programs. The Open Psychedelic Evaluation Nexus (OPEN) reviewed Oregon Health Authority-approved training programs and surveyed...
Journal of Psychoactive Drugs
January 29, 2025
Carrie Cuttler, Amanda Stueber, Jonathan J. Simone et al.
3 citations
The ever-changing landscape surrounding legality and accessibility of psychedelics and their increasing popularity make it imperative to better understand the nature of psychedelic use by the general population. To this end, 1,486 eligible respondents (Mage = 29.58, 67.1% male) residing in the United States completed an online survey designed to assess the types of psychedelics used, methods of...
Journal of Psychoactive Drugs
January 22, 2025
Mackenzie T Kiniry, Renee E Magnan, Sarah N Elder et al.
Recent research on the potential therapeutic value of psychedelic substances has led to changes in media representation and drug policy in some U.S. states. Yet, little is known about lay perceptions of these substances. The current study aimed to describe health perceptions of psychedelic substances, test differences in perceptions of therapeutic vs. recreational use of psychedelic substances,...
Journal of Psychoactive Drugs
January 10, 2025
Ana Cláudia Mesquita Garcia, Lucas Oliveira Maia, Everson Meireles et al.
8 citations
This study is a survey-type, cross-sectional study conducted in Brazil (n = 517), with online data collection taking place from April to June 2022. The main objective of this study was to evaluate the death anxiety in users and non-users of psychedelics. To this end, we also assessed the validity and reliability of the Death Anxiety Scale in Brazil. The following instruments were used for data...
Journal of Psychoactive Drugs
January 8, 2025
Valerio Ricci, Domenico de Berardis, Sheikh Shoib et al.
4 citations
This study explores the psychotic-like experiences (PLEs) associated with recreational ketamine use among young adults. Ketamine, initially introduced as an anesthetic, is now widely used recreationally for its dissociative effects, raising concerns about its impact on mental health. Ten participants aged 18-24, who used ketamine recreationally multiple times a week, were assessed using the...
Journal of Psychoactive Drugs
January 7, 2025
Matthew Hicks, Heather Zwickey, Ryan Bradley
2 citations
There are currently no evidence-based treatment guidelines for antisocial personality disorder (ASPD). Instead, treatment typically focuses on comorbid conditions. There is currently no literature documenting cases or research, theoretical or otherwise of using ketamine-assisted therapy or any other psychedelic therapy in cases of ASPD. In this case report, a 43-year-old man seeking...
Journal of Psychoactive Drugs
January 7, 2025
Fernando Espí Forcén
As psilocybin awaits approval by the Food and Drug Administration (FDA), scholars debate whether psychedelic-assisted psychotherapy should be required when prescribing this medicine. Here, we report the case of a patient who underwent a psilocybin experience without psychedelic-assisted psychotherapy, resulting in inpatient psychiatric admission. This case underscores the importance of taking...
Journal of Psychoactive Drugs
January 2, 2025
Petri Kajonius, David Sjöström, Emma Claesdotter-Knutsson
5 citations
In the midst of growing research and societal discourse on psychedelic substances, a consistent finding is reported: A majority of users report profound personal meaning from their experiences. This pioneering study in Sweden, a nation renowned for its strict drug policies, sought to quantify the extent of reported meaningfulness among Swedish psychedelic users. Results revealed that a majority...
Journal of Psychoactive Drugs
2025
Jacob S. Aday, Emily K. Bloesch, Alan K. Davis et al.
16 citations
Qualitative studies and anecdotal reports suggest that experiences with ayahuasca, a psychedelic brew found in Central and South America, may be followed by individuals enduringly feeling more grateful and connected to nature. Yet, to date, these changes have been understudied. Here, participants (N = 54) completed validated surveys related to gratitude, nature relatedness, and nature...
Journal of Psychoactive Drugs
2025
Elias C Acevedo, Scott Uhler, Kaitlyn P White et al.
15 citations
Interest in psychedelics and their possible therapeutic potential has been growing. Metaphysical belief theory asserts that these benefits stem from the adoption of comforting supernatural beliefs following a mystical experience. By contrast, predictive self-binding theory suggests that the beneficial outcomes of psychedelics are primarily driven by psychological insights. The present study...
Journal of Psychoactive Drugs
2025
Sean M. Viña
12 citations
Research has found that psychedelic use is associated with positive behavioral changes, however research has yet to explore the relationship between socio-cultural conditions on this relationship. This paper intends to fill this gap by testing the effects of religious participation and beliefs on the relationship between psychedelic use and behaviors. This study examines the relationship...
Journal of Psychoactive Drugs
2025
Ana Cláudia Mesquita Garcia, Lucas Oliveira Maia, Everson Meireles et al.
3 citations
This study evaluated the psychometric properties of the Spiritual Well-Being Scale (SWBS) in a Brazilian sample. We analyzed spiritual well-being, defined as existential well-being (EWB) and religious well-being (RWB), among individuals with varying religious and spiritual experiences, both users and non-users of psychedelics. The online cross-sectional survey was conducted in Brazil, from...
Journal of Psychoactive Drugs
2025
Morgan Hadley, Alicia Halliday, James Stone
1 citation
Hallucinogen Persisting Perception Disorder (HPPD) is considered rare in hallucinogen users although there are conflicting reports about its incidence and prevalence. HPPD may be more common in those with trait neuroticism. In this study, we invited hallucinogen and other drug users to complete an online questionnaire about their use of hallucinogens, their experience of HPPD symptoms, and...
Journal of Psychoactive Drugs
2025
Jamarie Geller, Nicolas G. Glynos, Andrew Lemmen et al.
This study aimed to characterize attitudes and identify gaps in trainee knowledge and education that may impact the field's readiness for the reemergence of psychedelic use in psychiatry. A two-part survey was sent out targeting medical and allied professional trainees who may interact with patients using or planning to use psychedelics therapeutically. Collected data for part one characterized...
Journal of Psychoactive Drugs
December 24, 2024
Omer A. Syed, Rotem Petranker, Emily C. Fewster et al.
3 citations
Although several studies have well described the characteristics of people who use psychedelics alongside their motivations and beliefs, little research has examined the preferences surrounding the source of psychedelic substances. In an anonymous online survey, we collected data from 6,379 consumers of 11 different psychedelic substances from 85 different countries, exploring their preferences...
Journal of Psychoactive Drugs
November 23, 2024
Daniel Perkins, Jerome Sarris, Tessa Cowley-Court et al.
5 citations
Emerging evidence indicates that ayahuasca consumption may have beneficial mental health effects. This study undertakes the largest analysis to date of associations between naturalistic ayahuasca use and current mental health status via an online cross-sectional survey. The sample included 7,576 participants (average age 41, 47% female) who had consumed ayahuasca in religious, traditional, or...
Journal of Psychoactive Drugs
November 22, 2024
Wesley C Ryan, Boris D. Heifets
2 citations
The use of ketamine and ketamine-assisted psychotherapy (KAP) for treatment of depression has grown dramatically, though much of these data are short term. The clinical profile of maintenance treatment remains poorly characterized. We assessed maintenance KAP for efficacy, tolerability, and reasons for dropout. This observational study retrospectively analyzed electronic health records from an...
Journal of Psychoactive Drugs
November 13, 2024
Reza Ghaffarzadegan, Mokhtar Karimi, Behnaz Hedayatjoo et al.
6 citations
Psilocybin-containing mushrooms, commonly known as magic mushrooms, drastically affect mental processing, cognitive functioning, and the mood state. In the present study, we investigated the effect of the Psilocybe cubensis extract on spatial memory and the brain-derived neurotrophic factor (BDNF) in rats exposed to chronic unpredictable mild stress (CUMS). The duration of CUMS was 4 weeks....